Login to Your Account

Other News To Note

Friday, August 10, 2012

• Curetis AG, of Holzgerlingen, Germany, and Cempra Inc., of Chapel Hill, N.C., signed a research and development collaboration to incorporate Curetis' molecular diagnostic system into Cempra's global Phase III trial of oral solithromycin in community-acquired bacterial pneumonia. The randomized, double-blind Phase III trial comparing solithromycin against a comparator drug is expected to begin in the fourth quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription